Roth v. Emergent Biosolutions Inc.

CourtDistrict Court, D. Maryland
DecidedDecember 23, 2021
Docket8:21-cv-01189
StatusUnknown

This text of Roth v. Emergent Biosolutions Inc. (Roth v. Emergent Biosolutions Inc.) is published on Counsel Stack Legal Research, covering District Court, D. Maryland primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Roth v. Emergent Biosolutions Inc., (D. Md. 2021).

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF MARYLAND Southern Division

PALM TRAN, INC. – AMALGAMATED * TRANSIT UNION LOCAL 1577 PENSION PLAN, *

–Individually and on Behalf of All * Others Similarly Situated– * Plaintiff, * v. Case No.: PWG-21-955 * EMERGENT BIOSOLUTIONS INC. et al., * Defendants. * * * * * * * * * * * * * * ALAN I. ROTH, *

Plaintiff, *

v. * Case No.: PWG-21-1189

EMERGENT BIOSOLUTIONS INC. et al., *

Defendants. *

* * * * * * * * * * * * * STEPHEN M. WEISS *

v. * Case No.: PWG-21-1368

* * * * * * * * * * * * * MEMORANDUM OPINION Before me are three federal securities class action lawsuits brought against Emergent BioSolutions Inc. (“Emergent”) and Individual Defendants—Robert G. Kramer, Sr., Richard S. Lindahl, and Syed T. Husain—for violations of Section 10(b) and 20(a) of the Exchange Act (15 U.S.C. §§ 78j(b) and 78t(a)) and Rule 10b-5 promulgated thereunder (17 C.F.R. § 240.10b-5). The Complaints in the three actions allege that Emergent and certain of its officers defrauded investors

in violation of the Exchange Act, and the disclosure of the alleged fraud caused the prices of Emergent securities to fall sharply, resulting in Plaintiffs’ losses. A series of motions have been filed seeking to consolidate the cases, appoint a lead plaintiff, and select lead counsel. See Summary of Motions Documents (with ECF Nos. in each case) on page 5.1 I have reviewed the motions and related filings and find a hearing unnecessary. See Loc. R. 105.6 (D. Md. 2021). For the following reasons, I shall consolidate the cases, appoint Nova Scotia Health Employees’ Pension Plan and the City of Fort Lauderdale Police & Firefighters’ Retirement System as Lead Plaintiffs, and approve the group’s selection of Pomerantz LLP as Lead Counsel and its selection of Cohen Milstein Sellers & Toll PLLC as Liaison Counsel.

BACKGROUND I. Factual Background Emergent is a Maryland-based biopharmaceutical company that provides products and solutions to address public health threats, including manufacturing services for vaccines and antibody therapeutics. Compl. ¶¶ 2, 20, ECF No. 1. During the COVID-19 pandemic, the United States government funded Operation Warp Speed to encourage rapid development, manufacturing, and distribution of COVID-19 vaccines,

1 For ease of reference herein, I shall refer only to the document ECF numbers in the first- filed case, PWG-21-955, unless otherwise noted. and Emergent was awarded approximately $628 million to reserve manufacturing space and upgrade its facilities at its Baltimore site. Id. at ¶¶ 2, 21. Emergent also signed agreements with Johnson & Johnson (“J&J”) and AstraZeneca worth a combined $875 million to provide large- scale manufacturing facilities to support the rapid supply of their vaccine doses to the public once they had been developed and approved. Id. Upon the announcements of these deals, Emergent’s

stock soared to new levels, peaking at over $134 per share on August 13, 2020. Id. at ¶ 4. Emergent touted its manufacturing expertise and its emphasis on quality control. Id. at ¶¶ 3, 23- 28. However, Plaintiffs allege that Emergent failed to disclose “myriad issues at its Baltimore facility that would detrimentally affect its ability to manufacture the vaccine.” Id. An FDA inspection revealed “a host of problems.” Id. at ¶ 4. On March 31, 2021, a media report revealed that Emergent employees had “mixed up” ingredients resulting in the contamination of up to 15 million doses of the J&J vaccine. Id. at ¶¶ 5, 30-31. It also was reported that millions of AstraZeneca vaccine doses had to be discarded due to spoilage by contamination. Id. at ¶ 7, 30-

31, 36. Reports also revealed that these were not isolated incidents, but part of a history of issues at the Baltimore plant. Id. at ¶¶ 5-7, 32, 36. In response, the government placed J&J in charge of the plant, prohibited it from producing the AstraZeneca vaccine, and as of April 2021, no doses of COVID-19 vaccines produced were released by the FDA for distribution. Id. at ¶¶ 7, 33. Unsurprisingly, as a result of this news, Emergent’s stock2 price fell from a close of $92.91 per share on March 31, 2021 to close at $78.62 on April 5, 2021. Id. at ¶¶ 8, 34. These lawsuits

2 Emergent’s common stock is traded on the New York Stock Exchange under the symbol “EBS.” Compl. ¶ 15. followed, alleging that Emergent and various executives had made false or misleading statements with material omissions. II. Procedural Background On April 19, 2021, Palm Tran, Inc. – Amalgamated Transit Union Local 1577 Pension Plan, individually and on behalf of others similarly situated, filed suit against Emergent, its

President and CEO, Robert Kramer Sr., its CFO, Richard Lindahl, and its Senior Vice President and Head of the Company’s CDMO3 business unit, Syed Husain. PWG-21-955. On May 14, 2021, Alan Roth, a Kentucky investor, filed a putative class action suit against the same Defendants. PWG-21-1189. And on June 2, 2021, an Emergent stockholder from Florida, Stephen Weiss, filed a putative class action suit against the same Defendants. PWG-21-1368. On June 18, 2021, Grand Slam Asset Management, LLC moved to consolidate the three related actions, and proposed that it be the lead plaintiff. ECF No. 13. On the same day, Mr. Weiss also moved to consolidate the three cases, and proposed himself as lead plaintiff. ECF No. 14. Three more motions were filed on June 21, 2021, requesting consolidation and appointment of a lead plaintiff. ECF Nos. 15, 16, 18. Movants and proposed lead plaintiffs were Lawrence

Edlund (ECF No. 15), the group of Nova Scotia Health Employees’ Pension Plan and the City of Fort Lauderdale Police & Firefighters’ Retirements System (“NS-FL Group”) (ECF No. 16), and the group Western Pennsylvania Funds, comprised of Western Pennsylvania Electrical Employees Insurance Trust Fund and Western Pennsylvania Electrical Employees Pension Fund (ECF No. 18). Following the filing of the NS-FL Group’s and Western Pennsylvania Funds’ motions, Mr. Weiss withdrew his motion, ECF No. 31, and Grand Slam Asset Management and Mr. Edlund

3 Contract Development and Manufacturing Organization (“CDMO”). Compl. ¶ 2. both filed notices of non-opposition to the competing motions, ECF Nos. 32, 33. The two remaining competing movants for lead plaintiff—NS-FL Group and Western Pennsylvania Funds—responded to each other’s motions and they are now fully briefed and ready for review. Summary of Motions Documents (with ECF Nos. in each case)

Motions & related documents Palm Tran Roth Weiss (21-955) (21-1189) (21-1368) Motion Consolidate & Appoint Lead - Grand 13 7 10 Slam Notice of Non-opposition to competing 32 10 15 motions Motion Consolidate & Appoint Lead - Weiss 14 9 Withdrawn due to competing motions 31 14 Motion Consolidate & Appoint Lead - Edlund 15 Notice of Non-opposition to competing 33 motions Motion Consolidate & Appoint Lead – NS- 16 8 11 FL Group Opposition by Western Pennsylvania Funds 34 Reply & Opp to Western Pennsylvania Funds 37 11 16 Motion Reply 12 17 Motion Consolidate & Appoint Lead - 18 Western Pennsylvania Funds Opposition by NS-FL Group 35 Reply 36 Supplemental Correspondence from NS-FL 38 Group Supplemental Authority from Western 39 Pennsylvania Funds (Koffsmon) Supplemental Authority response from NS- 40 FL Group

DISCUSSION The Private Securities Litigation Reform Act (the “PSLRA”) dictates the procedures a court must follow in resolving these motions. Under the statute, the court’s first task is to address any motions for consolidation. See 15 U.S.C.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

In Re: Cendant Corporation Litigation
264 F.3d 201 (Third Circuit, 1992)
Howard Gunty Profit Sharing Plan v. CareMatrix Corp.
354 F. Supp. 2d 18 (D. Massachusetts, 2000)
Aronson v. McKesson HBOC, Inc.
79 F. Supp. 2d 1146 (N.D. California, 1999)
In Re Microstrategy Inc. Securities Litigation
110 F. Supp. 2d 427 (E.D. Virginia, 2000)
China Agritech, Inc. v. Resh
584 U.S. 732 (Supreme Court, 2018)
In re Sequans Commc'ns S.A. Sec. Litig.
289 F. Supp. 3d 416 (E.D. New York, 2018)
Kaplan v. Gelfond
240 F.R.D. 88 (S.D. New York, 2007)
Foley v. Transocean Ltd.
272 F.R.D. 126 (S.D. New York, 2011)

Cite This Page — Counsel Stack

Bluebook (online)
Roth v. Emergent Biosolutions Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/roth-v-emergent-biosolutions-inc-mdd-2021.